The CDC Advisory Committee on Immunization Practices (ACIP) has resolved to lower the recommended age for pneumococcal vaccination from 65 to 50 years. 1
New recommendations recommend getting vaccinated at age 50 instead of age 65. Image credit: PRB ARTS – Stock.adobe.com
Following this announcement, both Merck and Pfizer issued statements praising ACIP’s decision. Both companies produce FDA-approved pneumococcal vaccines. ACIP also recommended that adults ages 19 to 49 who have certain underlying medical conditions or risk factors and who have not received a pneumococcal vaccine or whose vaccination history is unknown be vaccinated. CDC Director Mandy K. Cohen, MD, MPH supported these recommendations.
“The CDC’s decision to lower its age-based vaccination recommendations to begin at age 50 could be a milestone that will change the way we practice medicine,” said Merck’s Senior Vice President, Global Clinical Development Officer, and Chief Medical Officer. Director Eliav Barr said. 2 “This recommendation is an important step forward in efforts to strengthen equitable access and has the potential to improve vaccination rates.”
In a news release from Pfizer, Dr. Louis Jodard said the expanded use of Pfizer’s pneumococcal vaccine is due to “the re-emergence of pathogenic strains such as serotype 4, which has recently affected some adults in the United States.” It also provides an opportunity to limit the ” Jordahl is Pfizer’s senior vice president of vaccines and anti-infective medicines and chief medical officer.
The bacterium that causes pneumococcal pneumonia is Streptococcus pneumoniae. Infections are the leading bacterial cause of pneumonia hospitalizations in the United States. In addition, approximately 30,000 people contract invasive pneumococcal disease and 3,000 associated deaths occur each year. 4,5
Read more: Vaccine effectiveness and uptake become important for older adults as risk increases | ID Week 2024
There are currently four recommended pneumococcal vaccines6: PCV21, pneumococcal 21-valent conjugate vaccine (Capvaxive); PCV15, pneumococcal 15-valent conjugate vaccine (Vaxneuvance). PPSV23, polyvalent pneumococcal vaccine (Pneumovax 23), all manufactured by Merck. PCV20 is a pneumococcal 20-valent conjugate vaccine (Prevnar 20) manufactured by Pfizer.
Another potential vaccination option is currently under development. VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate produced by Vaxcyte. In early September, the company reported positive topline data from Phase 1/2 of VAX-31 (NCT06151288), which protects against all 31 serotypes that cause invasive pneumococcal disease. 7
Capvaxive was approved by the FDA in June 2024 and is effective against pneumococcal serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A in adults; 22F, 23A, 23B, 24F, 31, 33F and 35B, and active immunization for the prevention of pneumonia due to pneumococcal serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A in adults; 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B. 2 According to national CDC data from 2018 to 2022, the serotypes targeted by Capvaxive “are responsible for more cases of invasive pneumococcal disease in adults compared to PCV20.” said a Merck news release. “In adults aged 50 and older, Capvaxive covers the causative serotypes of approximately 84% of (invasive pneumococcal disease) cases, compared to approximately 52% for PCV20,” the company also said. , also noted that there are no current studies comparing the effectiveness of Capvaxive and Prevnar 20.2.
Prevnar 20 is for the prevention of invasive disease caused by pneumococcal strains 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, and 22F. has been adapted to. , 23F for individuals over 6 weeks old, and 33F. Active immunization for prevention of otitis media due to 7 of 20 strains in individuals from 6 weeks to 5 years of age and pneumonia due to pneumococcal strains 1, 3, 4, 5, 6A, 6B, and 7F, in adults. 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The indication for the prophylaxis of pneumonia caused by pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in adults is “approved on the basis of immune response.”3
Read more: Immunization Resource Center
References CDC recommends lowering the age for pneumococcal vaccination from 65 to 50 years. News release. CDC. October 23, 2024. Accessed October 24, 2024. https://www.cdc.gov/media/releases/2024/s1023-pneumococcal-vaccination.htmlCDC’s ACIP recommends Merck’s Capvaxive (pneumococcal 21-valent conjugate vaccine) for the following pneumococcal vaccinations: I am. Adults over 50 years old. News release. Merck. October 23, 2024. Accessed October 24, 2024. https://www.merck.com/news/cdcs-acip-recommends-mercks-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-pneumococcal-vaccination-in -Adults-50 years and older/Vaccination implementation The advisory committee recommends Prevnar 20 (20-valent pneumococcal conjugate vaccine) for adults aged 50 and older. News release. Pfizer. October 23, 2024. Accessed October 24, 2024. https://www.pfizer.com/news/press-release/press-release-detail/advisory-committee-immunization-practices-recommends Pneumococcal disease. National Foundation for Infectious Diseases. Accessed October 24, 2024. https://www.nfid.org/infectious-disease/pneumococcal/Kahn R, Zielinski L, Gedlinske A, et al. Health care provider knowledge and attitudes regarding adult pneumococcal conjugate vaccine recommendations — United States, September 28 to October 10, 2022. Morb Mortal Weekly Rep. 2023;72(36);979-984. About pneumococcal vaccine. CDC. Accessed October 24, 2024. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/about-vaccine.htmlVaxcyte is a 31-valent pneumococcal conjugate based on positive results from a Phase 1/2 study of VAX-31. Report topline data for vaccine candidates, adults 50 and older. News release. Baksite. September 3, 2024. October 24, 2024. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-reports-positive-topline-data-phase-12-study-vax-31- itsBiscaldi L. Approved vaccine Capvaxive. drug topic. June 18, 2024. Accessed October 24, 2024. https://www.drugtopics.com/view/fda-approves-pneumococcal-21-valent-conjugate-vaccine-capvaxive
Source link
